Cullinan Oncology, Inc. (CGEM)
NASDAQ: CGEM · IEX Real-Time Price · USD
16.31
-0.42 (-2.51%)
At close: Jul 2, 2024, 4:00 PM
16.49
+0.18 (1.10%)
After-hours: Jul 2, 2024, 5:12 PM EDT
Cullinan Oncology Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cullinan Oncology stock have an average target of 32, with a low estimate of 26 and a high estimate of 40. The average target predicts an increase of 96.20% from the current stock price of 16.31.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 3, 2024.
Analyst Ratings
The average analyst rating for CGEM stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 6 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +71.67% | Jun 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +71.67% | May 24, 2024 |
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +120.72% | May 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $29 → $28 | Strong Buy | Maintains | $29 → $28 | +71.67% | May 16, 2024 |
| Stifel | Stifel | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +145.25% | May 1, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
11.83M
EPS This Year
-3.09
from -3.69
EPS Next Year
-3.12
from -3.09
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 56.3M | 69.1M | 327.4M | 220.6M |
| Avg | n/a | 11.8M | 30.0M | 64.8M | 69.9M |
| Low | n/a | n/a | n/a | n/a | 3.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 484.6% | 991.1% | 240.3% |
| Avg | - | - | 153.7% | 116.1% | 7.8% |
| Low | - | - | - | - | -94.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.82 | -2.34 | -2.48 | 0.67 | -1.62 |
| Avg | -3.09 | -3.12 | -3.04 | -2.25 | -2.99 |
| Low | -3.28 | -4.13 | -4.66 | -4.41 | -4.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.